Last reviewed · How we verify
NCT06769191
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
EARLY_PHASE1 trial testing CD7 CAR-T cells injection in Schimke Immuno-osseous Dysplasia in 20 participants. Currently enrolling.
30 January 2028
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 30 January 2025 |
| Primary completion | 30 January 2028 |
| Estimated completion | 30 January 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD7 CAR-T cells injection — full drug profile →
- Allo-HSCT
- Kidney Transplantation
Conditions studied
- Schimke Immuno-osseous Dysplasia — all drugs for Schimke Immuno-osseous Dysplasia →
Sponsor
Zhejiang University
Who can join
Eligibility, any sex, with Schimke Immuno-osseous Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06769191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD7 CAR-T cells injection
Trials testing the same drug.
- NCT06787560 — CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases · EARLY_PHASE1 · recruiting
- NCT06633328 — CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia · EARLY_PHASE1 · recruiting
- NCT05827835 — CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases · Phase 1, PHASE2 · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06769191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06769191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing